EchoGo Amyloidosis vs Viz HCM
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, EchoGo Amyloidosis, is an AI-powered screening tool for the early detection of cardiac amyloidosis, analyzing echocardiogram video clips. Tool B, Viz HCM, is an AI tool that detects suspected hypertrophic cardiomyopathy using real-time ECG analysis and facilitates care coordination. While both are FDA-cleared, cloud-based cardiology AI solutions, they target different specific cardiac conditions and utilize distinct diagnostic inputs, making them adjacent rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. Viz HCM, on the other hand, uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and facilitate care coordination.
EchoGo Amyloidosis analyzes echocardiogram video clips to identify suspected cardiac amyloidosis. In contrast, Viz HCM performs real-time analysis of 12-lead electrocardiograms (ECGs) to detect signs associated with hypertrophic cardiomyopathy.
EchoGo Amyloidosis is priced per analysis, with Medicare-covered rates of $1,000 for inpatient (NTAP Code ICD-10 XXE2X19) and $285 for outpatient (HCPCS Code C9786, Clinical APC Code 574) analyses. Viz HCM is subscription-based for hospitals and health systems, with CMS reimbursement available for CPT codes 0764T and 0765T at a national payment rate of $128.90, effective January 1, 2025.
EchoGo Amyloidosis offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7 systems. Viz HCM is also a cloud-based platform integrated into hospital IT systems like EHR and PACS, designed to streamline cardiac care coordination and clinical workflows.
EchoGo Amyloidosis has demonstrated high diagnostic accuracy, with 85% sensitivity and 93% specificity for identifying cardiac amyloidosis. It also shows consistent performance across various cardiac amyloidosis subtypes, including AL, wild-type ATTR, and variant ATTR.
EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, focusing on early screening from echocardiogram video clips. Viz HCM, while detecting suspected HCM from ECGs, also emphasizes intelligent care coordination through mobile-based alerts and automated direction of patients to appropriate specialists.